Global CNS Therapeutics Industry (2020 to 2025) - Increased Spending on Prescription Drugs Bodes Well for the Market - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "CNS Therapeutics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

The global market for CNS Therapeutics is projected to reach US$137.7 billion by 2025, driven by the urgent need to address the unmet medical needs of neurological disorders. Diseases of the brain and mind range from epilepsy, stroke, migraine, Alzheimer`s, Parkinson`s, dementia, multiple sclerosis, brain injuries, neuroinfections, schizophrenia, psychosis and other mental disorders. With unmet needs continuing to persist, societal and healthcare burden continues to increase.

Stroke and infections such as meningitis and encephalitis continue to be the leading cause of disability worldwide, pushing up the cost of nursing care, hospice and bringing down quality of life. The unmet needs are evident in all phases of drug development i.e. identification of therapeutic targets; optimization of lead compounds; gaps in toxicity and pharmacokinetics studies; and slow resolution of ethical issues, among others. The need of the hour is innovation in developing more potent drugs and therapies. One of the reasons for the slower development of safe and effective drugs for neurology is the fact that the human brain is one of the most complex and highly organized organs in the universe.

The brain is a highly sophisticated piece of organic system perfected over millions of years of evolution. Scientists continue to struggle to fathom the complex interaction of chemicals and neurons in the brain. Investments in drug development in neurology is risky since certain diseases like neuropsychiatric diseases are difficult to target, are poorly defined, cannot be easily assayed, and pose challenges in efficiently validating clinical efficiency of drugs during clinical trials as most diseases progress slowly and develop over the years.

Strong opportunities for CNS focussed drugs therefore exists and compounding this need is the rapidly aging population and a parallel rise in Parkinson`s, Alzheimer`s, pain manifestations, cerebrovascular disorders, stroke, seizures, cognitive and memory disorders. The scenario has created a healthy global pipeline of late stage drugs and the market is expected to benefit from rising acceptance of new therapies and new classes of drugs; increased demand for combination therapies; growing use of generics; and launch of new Alzheimer`s drugs including anti-amyloid proteins, cholinergic and nicotine receptor agonists, neuro protective drugs, vaccines and GABA receptor modulators.

A key trend in the market is pharma companies` efforts to restrategize CNS drug development, which still continues to cost significantly higher than development costs in other therapeutic areas. Increased use of contract research organization services; and predictive planning to prevent late stage drug failure are few of the strategies adopted to infuse vigor in the CNS drug development space. The United States and Europe represent large markets worldwide with a combined share of 70% of the market. China ranks as the fastest growing market with a CAGR of 7.3% over the analysis period supported by factors such as changing social structures and increased risk of developing psychiatric disorders such as schizophrenia, sleep disorders, depression and anxiety; growing literacy rates, improved awareness and gradual reduction in the stigma associated with neurological disorders; and government policy led development of healthcare delivery systems.

Select Competitors (Total 181 Featured):

• AbbVie Inc.
• Alkermes Plc.
• Allergan Plc.
• AstraZeneca Plc.
• Bristol-Myers Squibb
• Eisai Co., Ltd.
• Eli Lilly and Co.
• Endo Pharmaceuticals Inc.
• F. Hoffmann-La Roche Ltd.
• GlaxoSmithKline Plc
• H. Lundbeck A/S
• Janssen Pharmaceuticals Inc.
• Merck & Co., Inc.
• Neurocrine Biosciences, Inc.
• Novartis AG
• Otsuka Pharmaceutical Co. Ltd.
• Pfizer Inc.
• Purdue Pharma L.P.
• Sanofi
• Shire Plc
• Sumitomo Dainippon Pharma Co., Ltd.
• Takeda Pharmaceutical Co., Ltd.
• Teva Pharmaceutical Industries Ltd.
• UCB Group

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

• Burgeoning Global Aging Populace, Longer Life Expectancy to Drive CNS Demand
• Increased Spending on Prescription Drugs Bodes Well for the CNS Therapeutics Market
• Rising Healthcare Expenditure to Boost CNS Therapeutics Market
• Growing Middle Class Population in Emerging Regions to Spur the Market
• Growing Penetration of Generic Drugs Emerges as a Key Trait
• Dollar Spending by Drug Category
• Developments in CNS Drug Delivery Technologies Bode Well for the CNS Drugs Market
• Understanding of BBB Cell Biology & Its Positive Impact on Epilepsy Drugs: A Case-in-Point
• Pharma Companies: Seeking New Tools to Offset Pressure on Drug Pipelines
• Awareness Campaigns Launched by Pharma Companies to Benefit the Market.
• Music and Memory Programs Positively Impact Alzheimer's Disease (AD) and Related Dementia (ADRD) Patients
• New Method to Isolate Active Compounds Related to Alzheimers from Plant Medicines

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

• Total Companies Profiled: 181

For more information about this report visit https://www.researchandmarkets.com/r/3yfgur

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900